All News

Individuals treated with remibrutinib demonstrated symptom control improvement in week 2 of the trial

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.

This FDA clearance comes about 11 months after another clearance for appliances to treat mild-to-moderate obstructive sleep apnea (OSA)—the first clearance for oral appliances to treat OSA with supplemental therapies.

Combination prevention strategies reduced the number of new HIV infections among gay and bisexual men who have sex with men; however, improvement of current methods is needed to meet the 2025 and 2030 reduction goals.

Kirollos Hanna, PharmD, BCPS, BCOP, FACC, discusses the multifaceted involvement of oncology pharmacists in various aspects of patient care.

In this episode, we spoke with Dr. Christina Madison, founder and CEO of The Public Health Pharmacist, about why abortion access and reproductive care are public health issues.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

In a phase 3 trial, none of the patients receiving nirogacestat reached median progression-free survival, indicating that it may effectively reduce disease progression.

The finding indicates that a potential vaccine can trigger a permanent response in individuals living with HIV-1.

Peanut sublingual immunotherapy offers a practical treatment option for peanut-allergic toddlers, reducing symptoms in 80% of children.

In addition to growing rates of STIs, there is concern for antimicrobial resistance to STIs.

The investigators note that continued support during breast cancer treatment is necessary for patient comfort beyond diagnosis and the initial phases of treatment.

The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.

Regardless of which of these vaccines patients receive, as long as they receive them according to the prescribed schedules, they can protect themselves and their community against the COVID-19 virus.

Tune in to this episode of the Independent Rx Forum for a comprehensive overview of the National Community Pharmacists Association's legislative priorities, updates on critical pharmacy-related bills, and insights into the legislative process.

A change in recurrence-free survival was also observed, with an 89% rate at 24 months in patients who achieved a complete pathologic response.

TcdBFBD, derived from a toxin found in Clostridium difficile, was tested in mouse models that mimicked different subtypes of breast cancer.

Although social determinants of health (SDOH) have been a major barrier to access of preexposure prophylaxis for those who are at risk of HIV, commercial determinants of health pose a similar barrier.

Study results indicate that outcomes were worse among those who inject illicit drugs and Black patients living with HIV.

Heart failure is a major cause of morbidity and mortality for adults with congenital heart disease (CHD), with the highest risk being for those with complex CHD lesions.

Major barriers to care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) can include navigating therapeutics and the cost of medications.

In crafting a patient-centered regimen, the convergence of expertise from physicians and pharmacists, paired with the values and preferences of patients, becomes paramount.

The study authors reported that plans in the South had the highest rates of exclusive PAs for either emtricitabine/tenofovir disoproxil fumarate or emtricitabine/tenofovir alafenamide even if the plan covered both, from 2018 to 2020.

The study findings indicate that health care professionals significantly underreport symptoms compared to patients with breast cancer, with reported comorbidities varying.

Pharmacies have the potential to introduce testing services, promote public health campaigns, collaborate with anemia-led clinics, and get more prescribing rights to diagnose anemia.